Bastian Gastl
Overview
Explore the profile of Bastian Gastl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
83
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jelgersma C, Alsolivany J, Akkas G, Wasilewski D, Gastl B, Misch M, et al.
Front Oncol
. 2025 Jan;
14():1430793.
PMID: 39839796
Tumor Treating Fields (TTFields) has emerged as a significant adjunctive component in the treatment of high-grade gliomas following the EF-14 trial in 2017. The incorporation of TTFields, alongside cyclic temozolomide...
2.
Klotz-Noack K, Klinger B, Rivera M, Bublitz N, Uhlitz F, Riemer P, et al.
Cell Rep
. 2020 Sep;
32(12):108184.
PMID: 32966782
Oncoproteins such as the BRAF kinase endow cancer cells with malignant properties, but they also create unique vulnerabilities. Targeting of BRAF-driven cytoplasmic signaling networks has proved ineffective, as patients regularly...
3.
Gastl B, Klotz-Noack K, Klinger B, Ispasanie S, Salib K, Zuber J, et al.
Cell Death Dis
. 2020 Jul;
11(7):499.
PMID: 32612138
To unravel vulnerabilities of KRAS-mutant CRC cells, a shRNA-based screen specifically inhibiting MAPK pathway components and targets was performed in CaCo2 cells harboring conditional oncogenic KRAS. The custom-designed shRNA library...
4.
Mamlouk S, Childs L, Aust D, Heim D, Melching F, Oliveira C, et al.
Nat Commun
. 2017 Jan;
8:14093.
PMID: 28120820
Genetic heterogeneity between and within tumours is a major factor determining cancer progression and therapy response. Here we examined DNA sequence and DNA copy-number heterogeneity in colorectal cancer (CRC) by...